Vertex Pharmaceuticals Cystic Fibrosis Treatment Approved for Young Children in EU
November 23 2023 - 8:54AM
Dow Jones News
By Adriano Marchese
Vertex Pharmaceuticals said its treatment Kaftrio has been
approved for a label expansion to treat children with cystic
fibrosis in the European Union.
The pharmaceutical company said Thursday that the European
Commission has granted approval for the label expansion of Kaftrio,
also known as ivacaftor, tezacaftor and elexacaftor, in combination
with ivacaftor to treat children between the ages of two and five
with cystic fibrosis.
Chief Medical Officer Carmen Bozic said the decision was based
on data from clinical trials as well as long-term and real-world
data that have shown the clinical benefit of Kaftrio in eligible
people who have CF.
Vertex said it already has a number of existing reimbursement
agreements with European countries, and that it will continue to
work with authorities to expand the list.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
November 23, 2023 09:39 ET (14:39 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Jul 2023 to Jul 2024